FDA Allows Expanded Enrollment in Clinical Study of Signature Biologics’ Investigational Cell Therapy for Duchenne ...
DALLAS--(BUSINESS WIRE)--Aug 11, 2026-- Signature Biologics, a clinical-stage cell therapy company committed to rigorous clinical research and to the DMD community, today announced that the U.S. Food and Drug Administration (FDA) has allowed expanded …